Talquetamab (tal) plus daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

被引：0
|
作者：
Dholaria, Bhagirathbhai R.
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Hartmut
Martin, Thomas G.
Morillo, Daniel
Reece, Donna Ellen
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar J.
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, Marie-Anne Damiette
Wasch, Ralph
van de Donk, Niels W. C. J.
Chari, Ajai
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Univ Hosp Salamanca, Salamanca, Spain
[4] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany
[5] Natl Ctr Tumorerkrankungen, Heidelberg, Germany
[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco Med Ctr, San Francisco, CA USA
[7] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
[9] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
[10] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[11] Med Coll Wisconsin, Milwaukee, WI USA
[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[14] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[15] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[16] Janssen Res & Dev, Spring House, PA USA
[17] Janssen Res & Dev, Antwerp, Belgium
[18] Janssen Biol Europe, Leiden, Netherlands
[19] Freiburg Univ, Med Ctr, Freiburg, Germany
[20] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[21] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8003
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)
    Yimer, Habte
    Melear, Jason
    Faber, Edward
    Bensinger, William I.
    Burke, John M.
    Gunawardena, Sriya
    Sean, Murphy
    Parros, Hollee
    Lutska, Yana
    Darif, Mohamed
    Londhe, Anil
    Qi, Ming
    Ukropec, Jon
    Lin, Thomas
    Rifkin, Robert M.
    BLOOD, 2017, 130
  • [32] Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001
    Facon, Thierry
    Lonial, Sagar
    Weiss, Brendan M.
    Suvannasankha, Attaya
    Fay, Joseph
    Arnulf, Bertrand
    Ifthikharuddin, Jainulabdeen J.
    de Boer, Carla
    Wang, Jianping
    Wu, Kaida
    Chari, Ajai
    Lentzsch, Suzanne
    Schecter, Jordan
    Krishnan, Amrita
    BLOOD, 2017, 130
  • [33] Healthcare Resource Use and Costs Among Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Romanus, Dorothy
    Seal, Brian
    Jhaveri, Mehul
    Labotka, Richard
    Henk, Henry
    BLOOD, 2015, 126 (23)
  • [34] Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.
    Ma, Xuewen
    Gong, Jue
    Zhou, Jie
    Yuan, Dongfen
    Vishwamitra, Deeksha
    Hilder, Brandi
    Masterson, Tara J.
    Tolbert, Jaszianne A.
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    Samtani, Mahesh N.
    Girgis, Suzette
    Berdeja, Jesus G.
    Krishnan, Amrita Y.
    Ouellet, Daniele
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)-Optimal dose, updated efficacy and safety results.
    Hajek, Roman
    Pour, Ludek
    Granell, Miquel
    Maisnar, Vladimir
    Richardson, Paul G.
    Norin, Stefan
    Sydvander, Malin
    Obermueller, Jakob
    Ocio, Enrique M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.
    Nahi, Hareth
    Usmani, Saad Zafar
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Yang, Shiyi
    Hellemans, Peter
    Tromp, Brenda J.
    Luo, Man
    Zemlickis, Donna
    Farnsworth, Andrew
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
    Lokhorst, Henk M.
    Laubach, Jacob
    Nahi, Hareth
    Plesner, Torben
    Gimsing, Peter
    Hansson, Markus
    Minnema, Monique
    Lassen, Ulrik Niels
    Krejcik, Jakub
    Ahmadi, Tahamtan
    Lisby, Steen
    Basse, Linda
    Brun, Nikolai C.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
    Mateos, Maria-Victoria
    Richardson, Paul
    Weisel, Katja
    Moreau, Philippe
    San-Miguel, Jesus
    Goldschmidt, Hartmut
    Orlowski, Robert
    Sonneveld, Pieter
    Reece, Donna E.
    Suzuki, Kenshi
    Bahlis, Nizar
    Yoon, Sung-Soo
    Spencer, Andrew
    Nooka, Ajay
    Hungria, Vania
    Plesner, Torben
    Ben Yehuda, Dina
    Pei, Huiling
    Mayo, Wendy Garvin
    Gai, Xue
    Carey, Jodi
    Carson, Robin
    Dimopoulos, Meletios A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S179 - S180
  • [39] Anchor (OP-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma (RRMM) - final efficacy and safety results
    Ocio, Enrique
    Efebera, Yvonne
    Hajek, Roman
    Straub, Jan
    Maisnar, Vladimir
    Eveillard, Jean-Richard
    Karlin, Lionel
    Mateos, Maria-Victoria
    Oriol, Albert
    Ribrag, Vincent
    Richardson, Paul
    Norin, Stefan
    Obermuller, Jakob
    Bakker, Nicolaas
    Pour, Ludek
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S204 - S204
  • [40] DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
    Lokhorst, H.
    Laubach, J.
    Nahi, H.
    Plesner, T.
    Gimsing, P.
    Hansson, M.
    Minnema, M.
    Lassen, U.
    Krejcik, J.
    Ahmadi, T.
    Khan, I.
    Uhlar, C.
    Lisby, S.
    Basse, L.
    Brun, N.
    Richardson, P.
    HAEMATOLOGICA, 2014, 99 : 106 - 107
12345